MK-677, also called ibutamoren or ibutamoren mesylate, is an orally active growth hormone secretagogue studied in multiple human randomized trials. Research shows effects on growth hormone and IGF-1 markers in some groups, but clinical benefits vary by condition, and MK-677 is not an FDA-approved medication. Safety, eligibility, and access questions require clinician review.
Wondering if sermorelin is right for you? Take the 3-min clinical quiz.
See if you qualify →What it is
MK-677 is an orally active small molecule and growth hormone secretagogue, meaning it is designed to stimulate growth hormone signaling. It is also called ibutamoren, ibutamoren mesylate, and MK-0677 in human studies 10.
In plain English: MK-677 tries to turn up a hormone pathway that affects growth hormone, insulin-like growth factor 1, body composition, bone turnover, and sleep-related biology. Human studies have looked at 7-day hormone profiles, two-month body-composition outcomes, sleep quality, bone markers, hip-fracture recovery, Alzheimer’s disease, and hemodialysis-related IGF-1 changes 3 4 5 6 9 12.
Names: MK-677, ibutamoren, and ibutamoren mesylate
- MK-677: the common research name used in many papers.
- Ibutamoren: another name used in clinical and supplement-marketing discussions.
- Ibutamoren mesylate: a salt form named in a phase IIb hip-fracture recovery trial 10.
- MK-0677: a closely related spelling used in several studies and trial records 3 5 10.
Evidence grade for MK-677
The assigned evidence grade for MK-677 is A because multiple human randomized controlled trials are indexed in PubMed, including trials in normal young men, obese subjects, postmenopausal osteoporotic women, hip-fracture recovery, Alzheimer’s disease, hemodialysis patients, and other groups 2 3 6 9 10 12.
Mechanism of action
MK-677 is described in human research as an oral ghrelin receptor agonist and growth hormone secretagogue. That means it acts on a pathway linked to ghrelin, growth hormone release, and downstream IGF-1 signaling 3 7.
Ghrelin-receptor agonism and growth hormone secretion
Ghrelin is a hormone involved in hunger and growth hormone signaling. MK-677 has been studied as an orally active compound that stimulates growth hormone secretion, including a human study that measured 24-hour GH profiles in normal young men after 7 days 9.
Mechanism does not equal outcome. A drug can change growth hormone or IGF-1 markers and still fail to improve a clinical endpoint, which is what makes the Alzheimer’s disease trial important: MK-677 was studied in a randomized trial and reported no clinical effect on Alzheimer’s disease progression 2.
Growth hormone, IGF-1, and downstream markers
Several studies focused on growth hormone, GH isoforms, insulin-like growth factor 1, bone turnover markers, fat-free mass, or energy expenditure. For example, one randomized blinded study in hemodialysis patients reported increased serum IGF-1 with MK-0677, while another study in obese subjects reported increased GH secretion, fat-free mass, and energy expenditure after two months 3 8 12.
Those findings are biologically interesting, but they are not proof that MK-677 improves lifespan, athletic performance, or long-term metabolic health. At Chia, we use this same standard when we discuss related growth-hormone-axis topics like sermorelin: mechanism is a starting point, not a guarantee.
Evidence
MK-677 has an evidence grade of A under the supplied rubric because two or more human randomized controlled trials exist. This grade describes the design and quantity of the literature, not whether MK-677 is effective for a given goal or safe for self-directed use.
A — two or more human randomised controlled trials. B — one human randomised trial, or two or more human clinical trials. C — human research exists, none of it randomised. D — animal or in-vitro research only; no human studies indexed. E — no trial evidence indexed in PubMed. The grade describes the quantity and design of published evidence, not whether the substance works, and not whether it is safe.
What human trials can and cannot prove
The human literature is broader than many online summaries suggest. Trials have studied MK-677 in diet-induced catabolism, obesity-related body composition, postmenopausal osteoporosis, hip-fracture recovery, Alzheimer’s disease, hemodialysis, sleep quality, and GH isoforms 1 2 3 4 6 8 10 12.
The hard part is that these endpoints are not the same. A change in IGF-1, fat-free mass, or bone turnover markers may not translate into better strength, fewer falls, slower disease progression, or longer life. Individual results vary, and the evidence does not support using MK-677 as a shortcut for bodybuilding or longevity claims.
Why biomarker changes are not the same as proven clinical benefit
One example is Alzheimer’s disease. Even though MK-677 acts on a hormone pathway, a randomized Alzheimer’s disease trial reported no clinical effect on disease progression 2.
Another example is bone research. MK-677 has been studied for markers of bone formation, bone resorption, and bone mineral density, but marker changes are not the same as showing fewer fractures or better long-term function 6 11.
Human outcomes studied so far
| Research area | What was studied | What the evidence can support | Key caution |
|---|---|---|---|
| Hormone signaling | 24-hour GH profiles, IGF-1, adrenocortical function, and GH isoforms | MK-677 has human evidence for changing GH/IGF-1-related markers 8 9. | Markers do not prove clinical benefit. |
| Body composition | Fat-free mass and energy expenditure in obese subjects | A two-month study reported increased GH secretion, fat-free mass, and energy expenditure 12. | This is not proof of safe bodybuilding use. |
| Bone | Bone turnover markers and bone mineral density | Studies exist in obese young males and postmenopausal osteoporotic women 6 11. | Bone markers are not the same as fracture reduction. |
| Hip-fracture recovery | Patients recovering from hip fracture | Randomized trials have studied MK-0677 in this setting 5 10. | Functional recovery is harder to prove than lab change. |
| Sleep | Sleep quality in humans | A human clinical trial studied prolonged oral treatment and sleep quality 4. | This does not establish treatment for sleep disorders. |
| Alzheimer’s disease | Clinical progression | A randomized trial reported no clinical effect on Alzheimer’s disease progression 2. | A negative clinical trial matters. |
| Hemodialysis | Serum IGF-1 in hemodialysis patients | A randomized blinded study reported increased serum IGF-1 3. | Kidney disease needs specialist-level risk review. |
What studies exist
| Year | Design | Study | Journal | Record |
|---|---|---|---|---|
| 1998 | Randomised controlled trial | MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism | The Journal of clinical endocrinology and metabolism | PMID 9467534 |
| 2008 | Randomised controlled trial | Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial | Neurology | PMID 19015485 |
| 2018 | Randomised controlled trial | Oral ghrelin receptor agonist MK-0677 increases serum insulin-like growth factor 1 in hemodialysis patients: a randomized blinded study | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association | PMID 28340044 |
| 1997 | Clinical trial | Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man | Neuroendocrinology | PMID 9349662 |
| 2004 | Randomised controlled trial | The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture | Journal of the American Geriatrics Society | PMID 15066065 |
| 2001 | Randomised controlled trial | Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporot | The Journal of clinical endocrinology and metabolism | PMID 11238495 |
| 1998 | Randomised controlled trial | Growth hormone secretagogues: mechanism of action and use in aging | Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society | PMID 10990440 |
| 2003 | Randomised controlled trial | The effect of treatment with the oral growth hormone (GH) secretagogue MK-677 on GH isoforms | Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society | PMID 12550076 |
| 1996 | Randomised controlled trial | Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical functio | The Journal of clinical endocrinology and metabolism | PMID 8768828 |
| 2011 | Randomised controlled trial | MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study | Archives of gerontology and geriatrics | PMID 21067829 |
| 1998 | Randomised controlled trial | Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research | PMID 9661080 |
| 1998 | Randomised controlled trial | Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure | The Journal of clinical endocrinology and metabolism | PMID 9467542 |
| Registration | Phase | Status | Enrolment | Title |
|---|---|---|---|---|
| NCT00074529 | PHASE2 | COMPLETED | 512 | Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED) |
| NCT01343641 | PHASE2 | WITHDRAWN | — | Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 Subjects |
| NCT00128115 | PHASE2 | TERMINATED | 83 | Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032) |
| NCT00116129 | PHASE2 | COMPLETED | 64 | Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia |
| NCT00395291 | NA | COMPLETED | 49 | Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients |
| NCT00474279 | PHASE1, PHASE2 | COMPLETED | 72 | Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older Adults |
| NCT05364684 | PHASE2 | COMPLETED | 12 | The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease |
| NCT06948214 | PHASE3 | RECRUITING | 150 | Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency |
This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-08.
Reported dosing ranges
MK-677 dosing should not be copied from the internet. The retrieved PubMed records confirm human study settings and durations, but they do not provide enough dose-detail text in the citation records to build a patient dosing plan.
The table below reports what can be stated from the retrieved human-study records. It is a study map, not a dosing guide. Doses used in published studies are not instructions for personal use; eligibility and monitoring require clinician evaluation.
| Source | Population or study setting | Dose amount available from retrieved record? | Duration or timing available from retrieved record | How to read this |
|---|---|---|---|---|
| Copinschi et al. 1996 9 | Normal young men | Not available in the retrieved citation text | 7-day treatment; 24-hour GH profiles measured | Shows a short human hormone-profile study, not personal dosing guidance. |
| Svensson et al. 1998 12 | Obese subjects | Not available in the retrieved citation text | Two-month treatment | Studied GH secretion, fat-free mass, and energy expenditure. |
| Murphy et al. 1998 1 | Diet-induced catabolism | Not available in the retrieved citation text | Not available in the retrieved citation text | Studied catabolism-related outcomes. |
| Copinschi et al. 1997 4 | Human sleep-quality study | Not available in the retrieved citation text | Prolonged oral treatment | Studied sleep quality; not a sleep-disorder dosing guide. |
| Murphy et al. 2001 6 | Postmenopausal osteoporotic women | Not available in the retrieved citation text | Not available in the retrieved citation text | Studied bone turnover and bone mineral density, alone and with alendronate. |
| Adunsky et al. 2011 10 | Patients recovering from hip fracture | Not available in the retrieved citation text | Phase IIb study | A clinical-trial setting, not a general recovery protocol. |
| Campbell et al. 2018 3 | Hemodialysis patients | Not available in the retrieved citation text | Not available in the retrieved citation text | Studied serum IGF-1 in a medically complex group. |
Why studied doses are not personal dosing instructions
Study dosing is chosen for a protocol, a population, and a safety-monitoring plan. A person reading online cannot know whether a study protocol fits their age, labs, glucose control, kidney function, cancer history, medications, or goals.
This is especially important for growth-hormone-axis compounds. Even for Chia-offered options such as sermorelin, our providers use an online health review, medical history, and ongoing messaging rather than one-size-fits-all dosing.
Legal status
Our regulatory log holds no confirmed federal action for MK-677. That means we have not found one with a primary source — not that none exists.
This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-08. See the full legal-status tracker for every compound we follow.
Safety
MK-677 safety cannot be reduced to “it raises IGF-1, so it is fine.” Human trials exist, but the retrieved records include varied populations, endpoints, and study designs, including older adults, postmenopausal women, hemodialysis patients, hip-fracture recovery, and Alzheimer’s disease research 2 3 5 6 10.
The retrieved citation records do not provide a full adverse-event table. That means this article should not claim a complete side-effect rate. It also means readers should not treat online side-effect lists as a substitute for clinician review.
Adverse events reported in human trials
The available PubMed records show that MK-677 has been studied in randomized and clinical trials, including medically complex groups such as hemodialysis patients and hip-fracture recovery patients 3 5 10. But the retrieved records supplied here do not include enough adverse-event detail to quote rates or rank side effects.
For a patient, the practical safety question is not “did any trial exist?” It is “would this hormone-axis intervention be reasonable for my health history, labs, medications, and goals?” That answer needs a licensed clinician.
Glucose, fluid retention, appetite, and related monitoring questions
Because MK-677 is studied through the growth hormone and IGF-1 pathway, a clinician would typically want to understand glucose-control history, swelling or fluid-retention symptoms, appetite and weight goals, kidney function, and other hormone-related treatments before making any risk judgment. The retrieved human studies support that MK-677 affects GH and IGF-1-related biology, but they do not supply a complete monitoring rule for patients 3 8 9 12.
Why bodybuilding use changes the risk discussion
Bodybuilding use often aims for muscle gain, fat-free mass, or performance. MK-677 has been studied for fat-free mass and energy expenditure in obese subjects, but that is not the same as proving safe muscle-building use in healthy lifters 12.
Stacking MK-677 with other research chemicals can add unknown risks because combination-specific human trials are not established in the retrieved evidence. If your goal is muscle or recovery education, our evidence-focused review of peptides for muscle growth explains why mechanism and marketing often get ahead of human outcomes.
Supply-chain risks
A separate safety issue is product quality. Material sold as “research use only” is not medical care and may not follow the same identity, impurity, sterility, storage, documentation, or pharmacist-review standards expected in a licensed pharmacy process.
This is why we steer readers away from self-sourcing and group-buy behavior. If you are comparing online peptide sources, our guide to peptide group buys explains the practical risks of identity, purity, and no-prescription supply chains.
Interactions
MK-677 interaction studies are not well defined in the retrieved records. The safer statement is that no clear interaction map can be built from the supplied PubMed records, not that interactions are absent.
Glucose-lowering medications
The retrieved evidence shows MK-677 has been studied for GH and IGF-1-related effects, including in hemodialysis patients and obese subjects 3 12. It does not provide a clear medication-interaction rule for people using insulin, GLP-1 medicines, metformin, sulfonylureas, or other glucose-lowering drugs.
If a person has diabetes, prediabetes, changing weight, or uses glucose-lowering medication, a clinician review is important before considering any hormone-axis compound. This is a risk-review point, not a dosing instruction.
Hormone-related therapies and growth-hormone-axis treatments
MK-677 is in the growth-hormone-axis conversation, but it is not the same as sermorelin or growth hormone. Sermorelin is a growth hormone-releasing hormone analog, while MK-677 is described as a ghrelin receptor agonist and growth hormone secretagogue 3 7.
At Chia, sermorelin is offered as injections, nasal spray, and tablets, with plans currently starting at $179/mo for injections. That does not make it interchangeable with MK-677; it means related hormone-axis questions should be handled through a clinician-guided review.
Other supplements or research chemicals marketed for muscle growth
The retrieved studies do not establish safety for combining MK-677 with bodybuilding peptides, selective androgen receptor modulators, hormone products, or multiple research chemicals. Combination use changes the risk picture because a person may not know the true identity, dose, impurity profile, or additive biologic effects of each product.
How to obtain it legally
MK-677 is education-only at Chia and is not offered by Chia. We do not prescribe, compound, sell, ship, or provide MK-677.
Start with a clinician evaluation rather than self-sourcing
The right process starts with a health history, medication list, goals, and risk review by a licensed clinician. A prescription, when appropriate for a treatment, requires a medical evaluation and is never guaranteed.
For treatments Chia does offer, our model is 100% online: a short health questionnaire, licensed US provider review, provider-guided dosing, pharmacy dispensing when prescribed, and home delivery. Chia medications are compounded in the US by state-licensed 503A compounding pharmacies; compounded drugs are not FDA-approved.
What a licensed pharmacy process is supposed to include
A licensed pharmacy process should include a valid prescription when required, pharmacist oversight, labeling, lot documentation, storage instructions, and a way to contact the care team. It should not depend on anonymous vials, group buys, or “research use only” material marketed directly to consumers.
Why research-chemical vendors are not medical care
Research-chemical vendors are not a substitute for a medical visit. They do not evaluate your glucose control, kidney history, cancer history, hormone-related risks, medication list, or whether a claimed compound matches what is actually in the container.
Chia note: MK-677 is education-only and is not offered by Chia
We publish pages like this because patients deserve clear evidence even when a compound is not in our catalog. If your actual goal is clinician-guided support for weight management, energy, or growth-hormone-axis questions, Chia offers separate treatments and protocols such as semaglutide, tirzepatide, sermorelin, and Weight + Muscle, depending on eligibility.
How does MK-677 compare with related growth-hormone-axis topics?
MK-677 sits in the same broad hormone-axis conversation as sermorelin and growth hormone, but it is not the same compound. The main difference is the target pathway: MK-677 is described as a ghrelin receptor agonist, while sermorelin acts through growth hormone-releasing hormone signaling.
| Topic | What it is | Human evidence in this article | Practical caution |
|---|---|---|---|
| MK-677 / ibutamoren | Oral small molecule; ghrelin receptor agonist; growth hormone secretagogue | Multiple human trials in GH/IGF-1, body composition, bone markers, sleep, hip fracture, Alzheimer’s disease, and hemodialysis research 2 3 4 6 10 12. | Biomarker changes do not prove longevity or bodybuilding outcomes. |
| Sermorelin | Growth hormone-releasing hormone analog | Not reviewed in this MK-677 evidence pool. | Related pathway, different compound; learn more in our guide to buying sermorelin online safely. |
| Growth hormone | Hormone in the GH/IGF-1 pathway | MK-677 studies measured GH secretion, GH isoforms, or downstream IGF-1 markers 8 9 12. | Changing GH biology is not the same as proving broad clinical benefit. |
| Bodybuilding peptides sold online | Often marketed for muscle, fat loss, or recovery | Combination-specific human evidence is not established in the retrieved MK-677 records. | Identity, purity, dose accuracy, and medical oversight may be unclear. |
If you are comparing growth-hormone-axis options, it helps to separate three questions: what pathway is being targeted, what human endpoints were studied, and what safety monitoring is needed. Our articles on oral sermorelin and sermorelin versus tesamorelin side effects go deeper on related but different compounds.
MK-677 has been studied for growth hormone and IGF-1 markers, fat-free mass, energy expenditure, bone markers, sleep quality, hip-fracture recovery, Alzheimer’s disease, and hemodialysis-related IGF-1 changes 1 2 3 4 5 6 8 9 10 11 12. The evidence does not prove longevity, bodybuilding, or broad disease-treatment benefits.
Yes. MK-677 is commonly called ibutamoren. Some studies also use the name ibutamoren mesylate or MK-0677 10.
MK-677 has been studied for fat-free mass and energy expenditure in obese subjects 12, but that does not prove safe or effective bodybuilding use. Muscle, performance, and long-term safety claims need stronger direct evidence.
The retrieved evidence for this article does not provide a clear human trial finding on hair loss. Anyone with hair changes, hormone concerns, or complex medication use should discuss this with a licensed clinician.
MK-677 has been studied in hemodialysis patients for serum IGF-1 effects 3, but that does not make it automatically safe for people with kidney disease. Kidney disease should be reviewed by a clinician before considering any hormone-axis compound.
The evidence here does not establish MK-677 as safe for bodybuilding. Bodybuilding use often involves higher-risk goals, stacking, self-sourcing, and products that may not have medical oversight.
No. MK-677 is education-only at Chia. Chia does not prescribe, compound, sell, ship, or provide MK-677.
References
- 1.PMID 9467534 [randomised controlled trial] Murphy MG, Plunkett LM, Gertz BJ, et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. The Journal of clinical endocrinology and metabolism. 1998.
- 2.PMID 19015485 [randomised controlled trial] Sevigny JJ, Ryan JM, van Dyck CH, et al. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology. 2008.
- 3.PMID 28340044 [randomised controlled trial] Campbell GA, Patrie JT, Gaylinn BD, et al. Oral ghrelin receptor agonist MK-0677 increases serum insulin-like growth factor 1 in hemodialysis patients: a randomized blinded study. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2018.
- 4.PMID 9349662 [clinical trial] Copinschi G, Leproult R, Van Onderbergen A, et al. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology. 1997.
- 5.PMID 15066065 [randomised controlled trial] Bach MA, Rockwood K, Zetterberg C, et al. The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture. Journal of the American Geriatrics Society. 2004.
- 6.PMID 11238495 [randomised controlled trial] Murphy MG, Weiss S, McClung M, et al. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. The Journal of clinical endocrinology and metabolism. 2001.
- 7.PMID 10990440 [randomised controlled trial] Fuh VL, Bach MA. Growth hormone secretagogues: mechanism of action and use in aging. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 1998.
- 8.PMID 12550076 [randomised controlled trial] Svensson J, Boguszewski CL, Shibata F, et al. The effect of treatment with the oral growth hormone (GH) secretagogue MK-677 on GH isoforms. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2003.
- 9.PMID 8768828 [randomised controlled trial] Copinschi G, Van Onderbergen A, L'Hermite-Balériaux M, et al. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men. The Journal of clinical endocrinology and metabolism. 1996.
- 10.PMID 21067829 [randomised controlled trial] Adunsky A, Chandler J, Heyden N, et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Archives of gerontology and geriatrics. 2011.
- 11.PMID 9661080 [randomised controlled trial] Svensson J, Ohlsson C, Jansson JO, et al. Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 1998.
- 12.PMID 9467542 [randomised controlled trial] Svensson J, Lönn L, Jansson JO, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. The Journal of clinical endocrinology and metabolism. 1998.
- 13.PubMed search results for ("MK-677" OR "Ibutamoren" OR "Ibutamoren mesylate"), with result counts and filters retrieved 2026-09-08.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if sermorelin is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
